Typhoid fever pathophysiology

Typhoid fever Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Typhoid fever from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X ray
CT
MRI
Ultrasound
Other Imaging Findings
Other diagnostic tests
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Typhoid fever pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Typhoid fever pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Typhoid fever pathophysiology
CDC on Typhoid fever pathophysiology
Typhoid fever pathophysiology in the news
Blogs on Typhoid fever pathophysiology
Directions to Hospitals Treating Typhoid fever
Risk calculators and risk factors for Typhoid fever pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pathophysiology

}}

Innoculation Orofecal transmission Infective dose 1000 to 1 million

Gastrointestinal Infection Stomach Enters stomach High tolerance for acid Survives PH as low as 1.5 Small intestine Adherence to mucosal cells Invade mucosal M cells overlying payers patches Internalisation in M cells Translocation to underlying lymphoid tissue and draining lymph nodes

Systemic spread Dissemination of S.typhi to reticuloendothelial system Spreads via lymph and blood Replication within reticuloendothelial system Evades immune system

Chronic carrier state Resides and multiplies in gall bladder Excretion in urine and stool

Heterozygous advantage

It is thought that cystic fibrosis may have risen to its present levels (1 in 1600 in UK) due to the heterozygous advantage that it confers against typhoid fever. The CFTR protein is present in both the lungs and the intestinal epithelium, and the mutant cystic fibrosis form of the CFTR protein prevents entry of the typhoid bacterium into the body through the intestinal epithelium.